Physician profile
Wallace Bret Smith
NPI 1164499836
$4,158.69
in general payments reported to CMS, 2019-2025
29 companies · $90.76 in 2025
The $90.76 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $894 · 2021: $777 · 2022: $575 · 2023: $551 · 2024: $407 · 2025: $90.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.51 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.25 | 2019-2024 | Skyrizi, Rinvoq |
| Pfizer INC. | $331.97 | 2019-2024 | |
| Leo Pharma INC. | $273.81 | 2021-2024 | Adbry |
| Lilly USA, LLC | $258.67 | 2019-2021 | |
| Dermavant Sciences, INC. | $251.87 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $175.86 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $170.23 | 2019-2021 | |
| Genzyme Corporation | $111.32 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $111.31 | 2019-2021 | |
| Janssen Biotech, INC. | $105.01 | 2021-2023 | Tremfya |
| Celgene Corporation | $97.94 | 2019 | |
| Sun Pharmaceutical Industries INC. | $94.48 | 2019-2024 | |
| Dermira, INC. | $71.94 | 2019-2021 | |
| Biofrontera INC. | $60.35 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.41 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $57.71 | 2023 | |
| Allergan, INC. | $52.14 | 2019-2021 | |
| Almirall LLC | $51.53 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $42.05 | 2020 | |
| Galderma Laboratories, L.P. | $41.68 | 2021 | |
| Organon LLC | $37.11 | 2025 | Vtama |
| Amgen INC. | $34.21 | 2020-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $33.33 | 2019 | |
| Journey Medical Corporation | $27.30 | 2019-2021 | |
| Krystal Biotech INC | $20.59 | 2023 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $19.52 | 2025 | Ycanth |
| Genentech USA, INC. | $18.10 | 2020 | |
| Ucb, INC. | $14.97 | 2019 | |
| Tactile Systems Technology INC | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.